Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.
- DOI
- 10.1007/s41669-022-00381-z
- Published
- 2022-12-01
- Container
- Pharmacoecon Open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s41669-022-00381-z,
title = {Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.},
author = {Martins P and Vandewalle B and Félix J and Capela CM and Cerqueira JJ and Salgado AV and Ferreira DG and Monteiro I.},
year = {2023},
journal = {Pharmacoecon Open},
doi = {10.1007/s41669-022-00381-z},
url = {https://doi.org/10.1007/s41669-022-00381-z}
}RIS
TY - JOUR TI - Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. AU - Martins P AU - Vandewalle B AU - Félix J AU - Capela CM AU - Cerqueira JJ AU - Salgado AV AU - Ferreira DG AU - Monteiro I. PY - 2023 JO - Pharmacoecon Open DO - 10.1007/s41669-022-00381-z UR - https://doi.org/10.1007/s41669-022-00381-z ER -
APA
P, M., B, V., J, F., CM, C., JJ, C., AV, S., DG, F., & I., M. (2023). Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.. Pharmacoecon Open. https://doi.org/10.1007/s41669-022-00381-z
Source records
- europe-pmc · retrieved 2026-09-27T02:06:40.646Z